Stock Market Reviews

SCNX (Scienture Holdings, Inc.) News

Get the latest news, insights, and market updates on SCNX (Scienture Holdings, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Scienture Holdings: Q3 Earnings Snapshot
  COMMACK, N.Y. (AP) — Scienture Holdings, Inc. SCNX) on Wednesday reported a loss of $3.6 million in its third quarter. On a per-share basis, the Commack, New York-based company said it had a loss of 19 cents.
  Nov 12, 2025 - $SCNX
• SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
  Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli™ (losartan potassium) Oral Suspension, 10
  Nov 4, 2025 - $SCNX
• EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives
  Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Tuesday that Arbli (losartan potassium) Oral Suspension, 10 mg/mL, has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans. The inclusion extends availability to over 100 million covered lives across the United States. In October, Scienture started commercial sales and fulfillment of the first customer orders for Arbli (losartan potassium) Oral Suspension
  Nov 4, 2025 - $SCNX
• BC-Most Active Stocks
  Nu Holdings Ltd. 17,689,966 16.115
  Nov 4, 2025 - $SCNX
• SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
  Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the de
  Oct 23, 2025 - $SCNX
• EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients
  Scienture Holdings, Inc. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies, announced Thursday that it started commercial sales and fulfillment of the first customer orders for Arbli (losartan potassium) Oral Suspension, 10 mg/mL. Arbli is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium for patients with hypertension who are 6 years and above and require an alternative to solid dosage forms. It is the first and onl
  Oct 23, 2025 - $SCNX
• SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
  Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to
  Oct 16, 2025 - $SCNX
• SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
  COMMACK, NY, Oct. 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that on October 3, 2025, it entered into an agreement (the “Agreement”) with Arena Finance Markets, LP and Arena Special
  Oct 8, 2025 - $SCNX
• SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
  Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on provi
  Oct 1, 2025 - $SCNX
• EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions
  Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Wednesday the formalization of multiple commercial group purchasing organization (GPO) agreements for its new drug, Arbli (losartan potassium) Oral Suspension, 10 mg/mL. The agreements will provide the company access to more than 2,500 healthcare institutions across the U.S., including hospitals, clinics, and long-term care facilities. The company stated that the deal represents a significant step for them as they seek to penetrate an estimated
  Oct 1, 2025 - $SCNX